This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Insider Buying at Auxilium, Aveo Hints At Big Moves in 2013

Stocks in this article: AUXLAVEOPFE

Given his history, Adams could be dressing up Auxilium for a sale.

Before that happens, Adams probably has to set a course for faster growth from Xiaflex and stabilize Testim sales. Once that's done, Auxilium could be ripe for a sale. All this makes Auxilium an interesting stock to follow for the next year.

Aveo is developing the kidney cancer drug tivozanib, currently under review at the FDA with an approval decision date of July 28, 2013. Investors have been punishing the stock because of worries about the approvability of tivozanib. In a pivotal phase III study, tivozanib delayed tumor progression and demonstrated a better safety profile than Onyx Pharma's (ONXX) Nexavar, but overall survival was greater for Nexavar than tivozanib.

Aveo has tried to explain away the survival benefit conundrum, insisting that patients treated with Nexavar in the pivotal trial "crossed over" to treatment with tivozanib as well. Still, the controversy has created an overhang on the stock.

Last week, Aveo CEO Tuan Ha-Ngoc purchased 75,000 shares of Aveo stock. Three directors also bought shares, including Henri Termeer, the former CEO of Genzyme. These insiders obviously betting that the FDA will approve tivozanib.

While many companies try to explain away doubts about clinical trial results, it's rare to see executives and directors talk with their wallets by buying significant amounts of their own stock. That's what Aveo insiders have done.

It will be quite interesting to see what happens next summer when tivozanib comes up for FDA approval. Before the decision, FDA is likely to convene an advisory panel to review the pivotal trial data. The confounding survival results will definitely be debated.

Rosenblum is long Auxilium and Aveo.

Dan Rosenblum has been a full-time stock trader since 1999 after leaving a job at a publicly held medical-device company. Rosenblum joined SharkInvesting.com that year and has been the online trading community's resident biotech expert ever since. Rosenblum writes the SharkBiotech.com newsletter, which has outperformed the S&P 500 and the Nasdaq Biotechnology Index every year since its inception in 2006. Rosenblum lives with his wife and kids in Rockland County, New York.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs